An association between TET2 CHIP carrier status, HF progression, and worse clinical outcomes was demonstrated through deep-targeted amplicon sequencing of bone-marrow-derived mononuclear cells in patients with chronic HF, with a dose–response relationship observed with increasing TET2 VAF [33]. Here, TET2 is linked to hydrops fetalis.